OTC Narcan and Leave-Behind Naloxone: The Legal Patchwork

The day naloxone left the prescription pad

On March 29, 2023, the FDA approved Narcan (naloxone hydrochloride) 4 mg nasal spray for over-the-counter, nonprescription use — the first naloxone product cleared to sell without a prescription. The FDA said the approval paved the way for the drug to be sold directly to consumers in places like drug stores, convenience stores, grocery stores and gas stations, as well as online, with the switch from prescription to OTC status expected to take months. That single regulatory action changed the legal terrain under every medic who responds to overdoses. Narcan is no longer the only OTC naloxone: the FDA approved RiVive 3 mg nasal spray as the second nonprescription naloxone product on July 28, 2023 — the same month it approved the first generic nonprescription naloxone nasal spray — and approved Rextovy 4 mg nasal spray as another OTC naloxone product on June 16, 2026.

Before OTC, naloxone access ran almost entirely through prescriptions and state standing orders — a physician's blanket authorization letting pharmacists or programs dispense without an individual script. OTC status didn't erase that machinery; it added a parallel retail channel. And that's where the patchwork gets confusing, because the rules governing what I can hand a patient from the back of my ambulance are state EMS rules, not the FDA's retail approval.

Prescription era vs. OTC / leave-behind

Leave-behind: handing the next dose to the people who'll use it

The operational shift that matters is the leave-behind naloxone program. Instead of reversing an overdose and walking away, EMS leaves one or more naloxone doses with the patient, family, or bystanders, plus brief education and a referral to treatment. The evidence base supports it: leave-behind improves linkage to care and reduces future fatal overdoses and repeat EMS workload. Maryland's program has run since 2018, and the Maryland Department of Health reports that EMS leave-behind programs there have distributed over 62,000 doses of naloxone to over 27,000 Marylanders since 2018; Arizona, Washington, North Carolina, and many others have built formal guidance.

But here's the catch — whether you, as a medic, are authorized to leave naloxone behind depends entirely on your state EMS office and your medical director's protocol. OTC approval did not automatically authorize EMS distribution. Some states issued explicit leave-behind protocols and standing orders; others are silent, leaving agencies to build their own policy on shaky footing.

The immunity patchwork nobody reads until it matters

Leave-behind only works if the people around an overdose will actually call 911 and use the naloxone without fear. That's the job of Good Samaritan overdose-immunity laws — and they are wildly inconsistent. All 50 states and D.C. now have some form of overdose Good Samaritan law; Wyoming, the last holdout, enacted its limited-immunity statute, W.S. § 35-7-1064, effective July 1, 2025. But scope varies dramatically:

• Iowa's immunity applies only once to a given overdose reporter and only once to a given overdose patient (Iowa Code § 124.418).
• Texas makes its overdose defense unavailable to people previously convicted of or placed on deferred adjudication for an offense under its controlled-substances, dangerous-drugs, or abusable-volatile-chemicals chapters, and to anyone who requested emergency medical assistance for a possible overdose during the preceding 18 months.

For harm reduction, those distinctions are life and death. If your community's bystanders don't trust that calling 911 won't get them arrested, the naloxone you leave behind sits in a drawer. This is the same regulatory unevenness that shapes other access questions in our field — the way the DEA telemedicine controlled-substance rules created a state-by-state scramble for buprenorphine and other treatment access.

What to document, and why

Leave-behind creates a documentation duty most ePCRs weren't built for. Record what you left, how many doses, the education you delivered, and any refusal. That record protects you, supports your agency's program reporting, and feeds the overdose surveillance data that justifies funding. It's also worth knowing where naloxone fits in the broader sedation-and-reversal picture — including the monitoring obligations after we chemically sedate an agitated patient, covered in chemical restraint and agitation protocols, where airway compromise can demand the same reversal readiness.

My take: OTC Narcan was the easy headline. The harder work is local — knowing your state's standing order, your agency's leave-behind authorization, and your community's exact Good Samaritan protections. Carry that knowledge the way you carry the drug.

Sources

• FDA — FDA Approves First Over-the-Counter Naloxone Nasal Spray
• FDA — Shelf-Life Extension for Naloxone Nasal Spray
• Network for Public Health Law — Statewide Naloxone Standing Orders Update (PDF)
• Washington State DOH — EMS Naloxone Leave-Behind Program Guidance (PDF)
• The Pew Charitable Trusts — State Policy Approaches to Expand Naloxone Access
• FDA — Information about Naloxone and Nalmefene
• FDA — FDA Approves Second Over-the-Counter Naloxone Nasal Spray Product
• FDA — FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose
• Maryland Department of Health — EMS Naloxone Leave-Behind
• Arizona Department of Health Services — Naloxone Leave Behind Program (PDF)
• North Carolina Department of Health and Human Services — Naloxone Distribution Toolkit (PDF)
• Wyoming Legislature — SF0074 Enrolled Act No. 63, W.S. § 35-7-1064 (PDF)
• Iowa Legislature — Iowa Code § 124.418 (PDF)
• Texas Legislature — HB 1694, 87th Legislature, overdose defense to prosecution

Reviewed against FDA and state pages on 18 October 2026.